Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590366 | 0.83 | MIF (0.56) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2590539 | 0.80 | MIF (0.62) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2587145 | 0.78 | MIF (0.59) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2587520 | 0.75 | MIF (0.64) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2590197 | 0.75 | MIF (0.53) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2548789 | 0.68 | MIF (0.52) | MIFNPC1POLBCD74MEN1 | |
| SCHEMBL14563270 | 0.68 | MIF (0.52) | MIFNPC1MAPTTP53POLB | |
| SCHEMBL2757855 | 0.68 | MIF (0.70) | MIFNPC1POLBCD74 | |
| SCHEMBL243468 | 0.68 | MIF (1.00) | MIFNPC1TP53POLBCD74 | |
| SCHEMBL2542424 | 0.67 | MIF (0.48) | MIFMAPTPOLBCD74MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | MIF 3416/4885NPC1 2612/4885MAPT 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.